Concepedia

Publication | Closed Access

Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer

373

Citations

26

References

2010

Year

Abstract

Sorafenib is reasonably well tolerated, with suggestion of clinical benefit for patients with sporadic MTC. Caution should be taken because of the rare but fatal toxicity potentially associated with sorafenib.

References

YearCitations

Page 1